Cardiology · 2008 · 26 citations · 0 references
MedicineEndocrinologyNuclear MedicineEndocrine Nuclear MedicineEndocrine OncologyMetastasisAdrenal TumorsEndocrine ImagingEndocrine Tumor DiagnosisEndocrine TumorsHormone-secreting TumorsRadioiodine TherapyEndocrine HypersecretionIodine-123 Metaiodobenzylguanidine ScintigraphyLocalization Imaging For PheochromocytomaPheochromocytoma DetectionPheochromocytoma DiagnosisTumor Regression Assessment
The newly developed radiopharmaceutical, 131I-metaiodobenzylguanidine (131I-MIBG), has been shown to be efficacious for the location of intra- and extra-adrenal, primary pheochromocytomas and metastatic, malignant pheochromocytomas (11.4% false-negative and 1.8% false-positive in patients with proven pheochromocytomas). Preliminary experience in selected patients with malignant pheochromocytoma suggest that therapy using large doses of 131I-MIBG results in partial tumor regression and improvement in catecholamine hypersecretion in some cases.